Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes

Research output: Contribution to journalJournal articlepeer-review

DOI

  1. Can we identify allergic rhinitis from administrative data: A validation study

    Research output: Contribution to journalJournal articlepeer-review

  2. The impact of socioeconomic status on the risk of total hip arthroplasty during 1995 to 2017 in Denmark

    Research output: Contribution to journalConference abstract in journalpeer-review

  3. All-cause mortality, suicide and self-harm in patients with treatment-resistant depression

    Research output: Contribution to journalJournal articlepeer-review

  4. GWAS of antidepressant treatment non-response in depression

    Research output: Contribution to journalJournal articlepeer-review

  1. Host Genetics and Antiviral Immune Responses in Adult Patients With Multisystem Inflammatory Syndrome

    Research output: Contribution to journalJournal articlepeer-review

  2. First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort study

    Research output: Contribution to journalJournal articlepeer-review

  3. Sex and age differences among tramadol users in three Nordic countries

    Research output: Contribution to journalJournal articlepeer-review

  4. Lungeemboli som medvirkende årsag til svær respirationsinsufficiens hos en patient med COVID-19

    Research output: Contribution to journalJournal articlepeer-review

  • Cristina Leal Rodríguez
  • Benjamin Skov Kaas-Hansen
  • Robert Eriksson
  • Jorge Hernansanz Biel
  • Kirstine G Belling
  • Stig Ejdrup Andersen
  • Søren Brunak
View graph of relations

PURPOSE: While the beneficial effects of medications are numerous, drug-drug interactions may lead to adverse drug reactions that are preventable causes of morbidity and mortality. Our goal was to quantify the prevalence of potential drug-drug interactions in drug prescriptions at Danish hospitals, estimate the risk of adverse outcomes associated with discouraged drug combinations, and highlight the patient types (defined by the primary diagnosis of the admission) that appear to be more affected.

METHODS: This cross-sectional (descriptive part) and cohort study (adverse outcomes part) used hospital electronic health records from two Danish regions (~2.5 million people) from January 2008 through June 2016. We included all inpatients receiving two or more medications during their admission and considered concomitant prescriptions of potentially interacting drugs as per the Danish Drug Interaction Database. We measured the prevalence of potential drug-drug interactions in general and discouraged drug pairs in particular during admissions and associations with adverse outcomes: post-discharge all-cause mortality rate, readmission rate and length-of-stay.

RESULTS: Among 2 886 227 hospital admissions (945 475 patients; median age 62 years [IQR: 41-74]; 54% female; median number of drugs 7 [IQR: 4-11]), patients in 1 836 170 admissions were exposed to at least one potential drug-drug interaction (659 525 patients; median age 65 years [IQR: 49-77]; 54% female; median number of drugs 9 [IQR: 6-13]) and in 27 605 admissions to a discouraged drug pair (18 192 patients; median age 68 years [IQR: 58-77]; female 46%; median number of drugs 16 [IQR: 11-22]). Meropenem-valproic acid (HR: 1.5, 95% CI: 1.1-1.9), domperidone-fluconazole (HR: 2.5, 95% CI: 2.1-3.1), imipramine-terbinafine (HR: 3.8, 95% CI: 1.2-12), agomelatine-ciprofloxacin (HR: 2.6, 95% CI: 1.3-5.5), clarithromycin-quetiapine (HR: 1.7, 95% CI: 1.1-2.7) and piroxicam-warfarin (HR: 3.4, 95% CI: 1-11.4) were associated with elevated mortality. Confidence interval bounds of pairs associated with readmission were close to 1; length-of-stay results were inconclusive.

CONCLUSIONS: Well-described potential drug-drug interactions are still missed and alerts at point of prescription may reduce the risk of harming patients; prescribing clinicians should be alert when using strong inhibitor/inducer drugs (i.e. clarithromycin, valproic acid, terbinafine) and prevalent anticoagulants (i.e. warfarin and non-steroidal anti-inflammatory drugs - NSAIDs) due to their great potential for dangerous interactions. The most prominent CYP isoenzyme involved in mortality and readmission rates was 3A4.

Original languageEnglish
JournalPharmacoepidemiology and Drug Safety
Volume31
Issue number6
Pages (from-to)632-642
Number of pages11
ISSN1053-8569
DOIs
Publication statusPublished - Jun 2022

Bibliographical note

© 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.

    Research areas

  • Aftercare, Aged, Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Clarithromycin, Cohort Studies, Cross-Sectional Studies, Denmark/epidemiology, Drug Interactions, Drug Prescriptions, Female, Hospitals, Humans, Male, Middle Aged, Patient Discharge, Prevalence, Terbinafine, Valproic Acid, Warfarin, drug–drug interactions, drug safety, electronic health records, pharmacoepidemiology, adverse outcomes, propensity score

ID: 77661219